Regression of Basal Cell Carcinomas in Multiple Sclerosis Patient on Aubagio Treatment

  • Judy Park DeWitt School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas
  • Kleesy L Thomas Department of Dermatology, Texas Tech University Health Sciences Center, Lubbock, Texas
  • Ashley Sturgeon Department of Dermatology, Texas Tech University Health Sciences Center, Lubbock, Texas
Keywords: Basal Cell Carcinomas, Multiple Sclerosis, Teriflunomide, Aubagio

Downloads

Download data is not yet available.

References

Soyer H, Rigel D, Wurm E. Actinic Keratosis, Basal Cell Carcinoma and Squamous Cell Carcinoma. In: Bolognia J, Jorizzo J, Schaffer J. Dermatology. 3rd ed. Philadelphia: Elsevier Saunders. 2012:108:1773-1793.

Bar-Or A, Pachner A, Menguy-Vacheron F, et al. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs. 2014;74:659-674.

Huang O, Zhang W, Zhi Q, et al. Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells. Experimental biology and medicine. 2015;240:426-437.

Published
2017-10-16
How to Cite
DeWitt, J. P., Thomas, K. L., & Sturgeon, A. (2017). Regression of Basal Cell Carcinomas in Multiple Sclerosis Patient on Aubagio Treatment. The Southwest Respiratory and Critical Care Chronicles, 5(21), 55-56. https://doi.org/10.12746/swrccc.v5i21.414